Home › Trials › NCT06602219

Evaluating LY4100511 for treating moderate-to-severe plaque psoriasis in adults

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study of LY4100511 (DC-853) for the Treatment of Adult Participants With Moderate-to Severe Plaque Psoriasis

Phase 2 Interventional Eli Lilly and Company · NCT06602219

This study is testing a new treatment called LY4100511 to see if it can help adults with moderate-to-severe plaque psoriasis feel better.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment220 (estimated)
Ages18 Years to 70 Years
SexAll
SponsorEli Lilly and Company Industry-sponsored
Locations58 sites (Birmingham, Alabama and 57 other locations)
Trial IDNCT06602219 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the safety and effectiveness of LY4100511, a new treatment, in adults suffering from moderate-to-severe plaque psoriasis. Participants will be randomly assigned to receive either the active treatment or a placebo. The study will monitor participants for any adverse effects and measure improvements in their psoriasis symptoms over time. The goal is to determine if LY4100511 can provide a better treatment option for this condition.

Who should consider this trial

Good fit: Ideal candidates are adults diagnosed with moderate-to-severe plaque psoriasis for at least six months and who meet specific health criteria.

Not a fit: Patients with certain types of psoriasis or those who have had recent significant flare-ups may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer significant relief and improved quality of life for patients with moderate-to-severe plaque psoriasis.

How similar studies have performed: Other studies have shown promise with similar treatments for plaque psoriasis, indicating potential for success with this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization
* Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).
* Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention.
* Must agree to avoid prolonged exposure to the sun and to refrain from the use of tanning booths, sun lamps, and other sources of ultraviolet light during the study

Exclusion Criteria:

* Have had a clinically significant flare of psoriasis during the 12 weeks before the baseline, as assessed by the investigator.
* Have a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis.
* Have any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus.
* Have a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic immunosuppressant medical treatment (including corticosteroids, immunosuppressants, and biologics).
* Have a current or recent acute, active infection. Participant must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment for at least 30 days before screening and up to randomization/baseline.

Where this trial is running

Birmingham, Alabama and 57 other locations

+8 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Plaque Psoriasis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.